Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease leading primarily to the inflammatory destruction of the synovial joints, ultimately resulting in loss of mobility and a decreased quality of life. Recent advances in RA-related research resulted in the introduction of Janus kinase (JAK) inhibitors to the therapeutic arsenal. JAK inhibitors are orally available and provide efficacy similar to that of disease-modifying anti-rheumatic drugs. However, due to the limited selectivity of these drugs, many RA patients experience adverse effects. The potential benefit of modulating protein tyrosine phosphatases, instead of inhibiting kinases, has not been explored. Using an animal model of RA, our group investigated the role of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) in inflammatory arthritis. The purpose of the present article is to highlight important conclusions of our previous paper entitled “Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase”. Herein we briefly present and discuss the observations of this study. We also outline future directions toward investigating the therapeutic potential of targeting SHP-1 in inflammatory arthritis in order to develop a new type of orally available drugs for the treatment of RA.
Highlights
The goal of this Commentary is to provide information about our recently published article “Regulation of autoimmune arthritis by the Src homology region domain-containing phosphatase 1 (SHP-1) tyrosine phosphatase”[1] and to highlight the relevance of our findings to arthritis-focused research and therapy
Since the role of SHP-1 in Rheumatoid arthritis (RA) or animal models of inflammatory arthritis has not been investigated before, we backcrossed the transgenic mice to the proteoglycan-induced arthritis (PGIA) susceptible BALB/c genetic background
When PGIA was induced in both transgenic genotypes, we found that mice homozygous for the Shp[1] transgene were almost fully resistant to the development of PGIA, while those with heterozygous transgene expression showed intermediate arthritis incidence and severity
Summary
The goal of this Commentary is to provide information about our recently published article “Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase”[1] and to highlight the relevance of our findings to arthritis-focused research and therapy. Using an animal model of RA, our group investigated the role of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) in inflammatory arthritis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
